Anavex Life Sciences Corp (AVXL)

[nidan7500]

see below as evidence supporting Xenalives post:

Two of the most significant biomarkers found in Alzheimer’s are decreased glucose uptake and the accumulation of amyloid plaques in the brain. PET scans use different radioactive drugs, called radiotracers, to measure these biomarkers within the brain tissue of patients with cognitive impairment. FDG-PET is one of the most commonly used imaging techniques to diagnose Alzheimer’s. However, in recent years, several other radiotracers, such as florbetapir, have been developed to detect the deposition of amyloid plaques.

Recently, the effectiveness of amyloid imaging as a strategy for monitoring dementia symptoms has been called into question. While the presence of amyloid plaques in the brain is considered as being characteristic of Alzheimer’s, some studies have shown that large amounts of amyloid plaques were present in healthy, non-demented individuals. Conversely, recent clinical trials have shown that the intended removal of amyloid from the brains of patients with Alzheimer’s disease led to no change in, or even worsened, cognitive performance.

IMO, there is a massive pile of evidence which clearly contradicts FDA claims of any certain causal links . Why-how the FDA have continued w/this is baffling.

https://www.pennmedicine.org/news/news-releases/2019/august/measuring-brains-amyloid-buildup-less-effective-alzehimers-disease-compared-imaging-methods#:~:text=While%20the%20presence%20of%20amyloid,